Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus

Vaccine

Volumn 28, Issue 11, 2010, Pages 2271-2276

  Kortekaas, J ^a   Dekker, A ^a   de Boer, S M ^a,b   Weerdmeester, K ^a   Vloet, R P M ^a   Wit, A A C de ^a   Peeters, B P H ^a   Moormann, R J M ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b Department of Infectious Diseases and Immunology   (Netherlands)

Author keywords

Intramuscular; Newcastle disease virus; Rift Valley fever virus; Vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; NEWCASTLE DISEASE VIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CALF (BOVINE); DRUG POTENCY; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INOCULATION; NONHUMAN; PRIORITY JOURNAL; RIFT VALLEY FEVER BUNYAVIRUS; VIRUS RECOMBINANT;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CATTLE; GENETIC VECTORS; INJECTIONS, INTRAMUSCULAR; NEWCASTLE DISEASE VIRUS; RIFT VALLEY FEVER VIRUS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 77049094863     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.001     Document Type: Article

References (45)

1. Bird B.H., Ksiazek T.G., Nichol S.T., and Maclachlan N.J. Rift Valley fever virus. J Am Vet Med Assoc 234 7 (2009) 883-893
2. Coetzer J.A. The pathology of Rift Valley fever. I. Lesions occurring in natural cases in new-born lambs. Onderstepoort J Vet Res 44 4 (1977) 205-211
3. Coetzer J.A. The pathology of Rift Valley fever. II. Lesions occurring in field cases in adult cattle, calves and aborted foetuses. Onderstepoort J Vet Res 49 1 (1982) 11-17
4. Al-Hazmi M., Ayoola E.A., Abdurahman M., Banzal S., Ashraf J., El-Bushra A., et al. Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin Infect Dis 36 3 (2003) 245-252
5. McIntosh B.M., Russell D., dos Santos I., and Gear J.H. Rift Valley fever in humans in South Africa. S Afr Med J 58 20 (1980) 803-806
6. Barnard B.J. Rift Valley fever vaccine-antibody and immune response in cattle to a live and an inactivated vaccine. J S Afr Vet Assoc 50 3 (1979) 155-157
7. Barnard B.J., and Botha M.J. An inactivated rift valley fever vaccine. J S Afr Vet Assoc 48 1 (1977) 45-48
8. Harrington D.G., Lupton H.W., Crabbs C.L., Peters C.J., Reynolds J.A., and Slone Jr. T.W. Evaluation of a formalin-inactivated Rift Valley fever vaccine in sheep. Am J Vet Res 41 10 (1980) 1559-1564
9. Botros B., Omar A., Elian K., Mohamed G., Soliman A., Salib A., et al. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J Med Virol 78 6 (2006) 787-791
10. Smithburn K.C. Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol 30 1 (1949) 1-16
11. Fauquet C.M., Mayo M.A., Maniloff J., Desselberger U., and Ball LA. Virus Taxonomy: Eighth Report of the International Committee on Taxonomy of Viruses (2005), Academic Press, An Imprint of Elsevier
12. Alexander D.J. Newcastle disease and other paramyxovirus infections. In: Calnek B.W., Barnes H.J., Beard C.W., McDougal L.R., and Saif Y.M. (Eds). Diseases of Poultry. 10th edn (1997), Iowa State University Press, Ames 541-569
13. Zhao H., and Peeters B.P. Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication. J Gen Virol 84 (2003) 781-788
14. Huang Z., Elankumaran S., Yunus A.S., and Samal S.K. A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV. J Virol 78 18 (2004) 10054-10063
15. Park M.S., Steel J., Garcia-Sastre A., Swayne D., and Palese P. Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci USA 103 21 (2006) 8203-8208
16. Veits J., Wiesner D., Fuchs W., Hoffmann B., Granzow H., Starick E., et al. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc Natl Acad Sci USA 103 21 (2006) 8197-8202
17. Bukreyev A., Skiadopoulos M.H., Murphy B.R., and Collins P.L. Nonsegmented negative-strand viruses as vaccine vectors. J Virol 80 21 (2006) 10293-10306
18. Bukreyev A., and Collins P.L. Newcastle disease virus as a vaccine vector for humans. Curr Opin Mol Ther 10 1 (2008) 46-55
19. Bukreyev A., Huang Z., Yang L., Elankumaran S., St Claire M., Murphy B.R., et al. Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol 79 21 (2005) 13275-13284
20. DiNapoli J.M., Kotelkin A., Yang L., Elankumaran S., Murphy B.R., Samal S.K., et al. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci USA 104 23 (2007) 9788-9793
21. Dinapoli J.M., Ward J.M., Cheng L., Yang L., Elankumaran S., Murphy B.R., et al. Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans. Vaccine 27 10 (2009) 1530-1539
22. DiNapoli J.M., Yang L., Suguitan Jr. A., Elankumaran S., Dorward D.W., Murphy B.R., et al. Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J Virol 81 21 (2007) 11560-11568
23. Subbiah M., Yan Y., Rockemann D., and Samal S.K. Experimental infection of calves with Newcastle disease virus induces systemic and mucosal antibody responses. Arch Virol 153 6 (2008) 1197-1200
24. Gorchakov R., Volkova E., Yun N., Petrakova O., Linde N.S., Paessler S., et al. Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins. Virology 366 1 (2007) 212-225
25. Wallace D.B., Ellis C.E., Espach A., Smith S.J., Greyling R.R., and Viljoen G.J. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 24 49-50 (2006) 7181-7189
26. Schmaljohn C.S., Parker M.D., Ennis W.H., Dalrymple J.M., Collett M.S., Suzich J.A., et al. Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 170 1 (1989) 184-192
27. Peeters B.P., de Leeuw O.S., Koch G., and Gielkens A.L. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 73 6 (1999) 5001-5009
28. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 2 (1991) 193-199
29. Britton P., Green P., Kottier S., Mawditt K.L., Penzes Z., Cavanagh D., et al. Expression of bacteriophage T7 RNA polymerase in avian and mammalian cells by a recombinant fowlpox virus. J Gen Virol 77 (1996) 963-967
30. Calain P., and Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 67 8 (1993) 4822-4830
31. Peeters B.P., Gruijthuijsen Y.K., de Leeuw O.S., and Gielkens A.L. Genome replication of Newcastle disease virus: involvement of the rule-of-six. Arch Virol 145 9 (2000) 1829-1845
32. Filone C.M., Heise M., Doms R.W., and Bertolotti-Ciarlet A. Development and characterization of a Rift Valley fever virus cell-cell fusion assay using alphavirus replicon vectors. Virology 356 1-2 (2006) 155-164
33. Lamb R.A., and Kolakofsky D. Paramyxoviridae: The Viruses and Their Replication (1996)
34. Galinski M.S., and Wechsler S.L. The Molecular Biology of the Paramyxovirus Genus (1991), Plenum Press, New York, NY
35. Panda A., Huang Z., Elankumaran S., Rockemann D.D., and Samal S.K. Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Microb Pathog 36 1 (2004) 1-10
36. Nakaya T., Cros J., Park M.S., Nakaya Y., Zheng H., Sagrera A., et al. Recombinant Newcastle disease virus as a vaccine vector. J Virol 75 23 (2001) 11868-11873
37. Krishnamurthy S., Huang Z., and Samal S.K. Recovery of a virulent strain of Newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology 278 1 (2000) 168-182
38. Garry C.E., and Garry R.F. Proteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes). Theor Biol Med Model 1 (2004) 10
39. Blach-Olszewska Z. Interferon induction by Newcastle disease virus in mice. Arch Immunol Ther Exp (Warsz) 18 4 (1970) 418-441
40. Brehm G., and Kirchner H. Analysis of the interferons induced in mice in vivo and in macrophages in vitro by Newcastle disease virus and by polyinosinic-polycytidylic acid. J Interferon Res 6 1 (1986) 21-28
41. Biron C.A. Interferons alpha and beta as immune regulators-a new look. Immunity 14 6 (2001) 661-664
42. Honda K., Sakaguchi S., Nakajima C., Watanabe A., Yanai H., Matsumoto M., et al. Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci USA 100 19 (2003) 10872-10877
43. Le Bon A., Etchart N., Rossmann C., Ashton M., Hou S., Gewert D., et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 4 10 (2003) 1009-1015
44. Santini S.M., Lapenta C., Logozzi M., Parlato S., Spada M., Di Pucchio T., et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191 10 (2000) 1777-1788
45. Martinez-Sobrido L., Gitiban N., Fernandez-Sesma A., Cros J., Mertz S.E., Jewell N.A., et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol 80 3 (2006) 1130-1139